

## Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Apotex Inc. and Pharmascience Inc. that the shortages of Apo-Doxylamine/B6 10 mg/10 mg Sustained-Release Tablet (DIN 02413248) and pms-Doxylamine-Pyridoxine 10 mg/10 mg Sustained-Release Tablet (DIN 02406187) respectively, have been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **October 22, 2018**.

### DOXYLAMINE SUCCINATE/ PYRIDOXINE HCL

#### 10 MG \* 10 MG SUSTAINED-RELEASE TABLET

00002413248	APO-DOXYLAMINE/B6	APX	\$ 0.6402
00002406187	PMS-DOXYLAMINE-PYRIDOXINE	PMS	\$ 0.6402
00000609129	DICLECTIN	DUI	\$ 1.2803

Alberta Blue Cross has been advised by Apotex Inc. that the shortage of Apo-Levocarb CR 200/50 mg Extended-Release Tablet (DIN 02245211) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **October 25, 2018**.

### LEVODOPA/ CARBIDOPA

#### 200 MG \* 50 MG SUSTAINED-RELEASE TABLET

00002245211	APO-LEVOCARB CR	APX	\$ 0.7115
00000870935	SINEMET CR 200/50	MFC	\$ 1.4550

... continued from previous page

## Removal of temporary benefits from the Alberta Drug Benefit List (ADBL)

Due to the shortage of Acetylcysteine 20% Inhalation Solution (DIN 02243098) manufactured by Sandoz Canada Inc., Acetylcysteine 20% Inhalation Solution (DIN 02300435) manufactured by Alveda Pharmaceuticals Inc. and Acetylcysteine 20% Inhalation Solution USP (DIN 02459906) manufactured by Teligent were added as temporary benefits for the *Alberta Drug Benefit List (ADBL)*.

Sandoz Canada Inc. has advised Alberta Blue Cross that the shortage of Acetylcysteine 20% Inhalation Solution (DIN 02243098) has been resolved.

As a result, Acetylcysteine 20% Inhalation Solution (DIN 02300435) and Acetylcysteine 20% Inhalation Solution USP (DIN 02459906) will no longer be considered temporary benefits for the *ADBL* **after October 16, 2018**.

---

Due to the shortage of Altace HCT 5 mg/12.5 mg Tablet (DIN 02283158) manufactured by Valeant Canada LP, Ran-Ramipril HCTZ 5 mg/12.5 mg Tablet (DIN 02449447) manufactured by Ranbaxy Pharmaceuticals Canada Inc was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Valeant Canada LP has advised Alberta Blue Cross that the shortage of Altace HCT 5 mg/12.5 mg Tablet (DIN 02283158) has been resolved.

As a result, Ran-Ramipril HCTZ 5 mg/12.5 mg Tablet (DIN 02449447) will no longer be considered a temporary benefit for the *ADBL* **after October 25, 2018**.

---

### When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

**780-498-8370** (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free)

**FAX 780-498-8406** (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefits and supplemental claiming information to assist with the submission of your direct bill drug claims. **Visit** [ab.bluecross.ca/providers/pharmacy-home.php](http://ab.bluecross.ca/providers/pharmacy-home.php)



\*\*The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. \*† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.763 2018/09

